- Oral presentation of intravenous
VRDN-001 preclinical and Phase 1/2 clinical data –
- Poster presentations of subcutaneous VRDN-003
preclinical data –
- Subcutaneous program selection for thyroid
eye disease (TED) on track for year-end 2023, and VRDN-001 THRIVE
Phase 3 topline results in active TED on track for mid-2024 –
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that multiple abstracts featuring clinical and
preclinical data on the company’s pipeline candidates for the
treatment of thyroid eye disease (TED) will be presented at the
2023 Annual Meeting of the American Academy of Ophthalmology (AAO
2023), to be held November 3-6, 2023, in San Francisco,
California.
In an oral presentation, encore data for intravenous VRDN-001
including preliminary clinical results from a Phase 1/2 study will
be highlighted. VRDN-001 is a full antagonist antibody targeting
the insulin-like growth factor-1 receptor (IGF-1R) and is currently
in two Phase 3 clinical studies for active and chronic TED
respectively. Viridian will also present encore preclinical data
for VRDN-003, which is a half-life extended antibody targeting
IGF-1R that is designed to be a potentially best-in-class,
self-administered, infrequent, and low-volume injection for
patients. Subcutaneous VRDN-003 is currently in a Phase 1 clinical
study in healthy volunteers to evaluate its pharmacokinetics and
safety. Viridian is on track to select its lead subcutaneous IGF-1R
program by year end 2023 and expects VRDN-001 THRIVE Phase 3
topline results in active TED in mid-2024, both as previously
disclosed.
Oral Presentation Title: VRDN-001, a Full Antagonist
Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): In Vitro
Pharmacology and Clinical Phase 1/2 Results Session: OP02
Neuro-Ophthalmology Original Papers Information: Saturday, November
4, 9:45 to 10:52 a.m. PST
Poster Presentations Title: Antagonist Properties of
VRDN-003, a Next-Generation, Half-life Extended Antibody to IGF-1
Receptor for Thyroid Eye Disease (TED) Session: PT10
Oculoplastics Poster Theater Information: Sunday, November 5, 3:45
to 4:45 p.m. PST (Presentation time: 4:09 to 4:15 p.m. PST)
Title: VRDN-003, a Novel Half-life Extended IGF-1 Receptor
Antibody for Thyroid Eye Disease (TED): Preclinical PK Data
Session: Electronic Poster Information: On-Demand access available
throughout the meeting
About TED
TED is a serious and debilitating rare autoimmune disease that
causes inflammation within the orbit of the eye that can cause
double vision, pain, and potential blindness. TED is a progressive
disease consisting of an initial active phase, followed by a
transition to a secondary chronic phase. More than 50,000 and
200,000 people are estimated to suffer from active and chronic TED,
respectively, in the United States and Europe.
About Viridian Therapeutics
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with TED. The company is conducting two
global Phase 3 studies (THRIVE and THRIVE-2) to evaluate the safety
and efficacy of VRDN-001 in patients with active and chronic TED.
Simultaneously, the company is developing its subcutaneous program
strategy with the goal of providing a potentially more conveniently
administered therapy to patients with TED. In addition to its TED
portfolio, Viridian is advancing a novel portfolio of FcRn
inhibitors with the potential to be developed in multiple
autoimmune diseases. Viridian is also developing additional
preclinical assets in autoimmune and rare diseases.
Viridian is based in Waltham, Massachusetts. For more
information, please visit www.viridiantherapeutics.com. Follow
Viridian on LinkedIn and X.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "plan,"
"potential," "predict," "project," "should," "target," "will," or
"would" or other similar terms or expressions that concern our
expectations, plans and intentions. Forward-looking statements
include, without limitation, statements regarding our expectations,
strategies, plans and intentions. Forward-looking statements are
neither historical facts nor assurances of future performance.
Instead, they are based on our current beliefs, expectations, and
assumptions. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. No representations or warranties (expressed or
implied) are made about the accuracy of any such forward-looking
statements. Such forward-looking statements are subject to a number
of material risks and uncertainties including but not limited to
the timing, progress and plans for our ongoing or future research,
pre-clinical and clinical development programs, including for
VRDN-003 and other risks and uncertainties, including those risks
set forth under the caption "Risk Factors" in our Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission
(SEC) on August 8, 2023 and other subsequent disclosure documents
filed with the SEC. Any forward-looking statement speaks only as of
the date on which it was made. Neither the Company, nor its
affiliates, advisors, or representatives, undertake any obligation
to publicly update or revise any forward-looking statement, whether
as a result of new information, future events or otherwise, except
as required by law. These forward-looking statements should not be
relied upon as representing the Company’s views as of any date
subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231103220943/en/
Investors: Louisa Stone, 508-808-2400 Manager, Investor
Relations IR@viridiantherapeutics.com
Media: Matt Fearer, 617-272-4605 Vice President, Corporate
Communications Media@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Apr 2024 to May 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From May 2023 to May 2024